Digestive Diseases and Sciences

, Volume 50, Issue 9, pp 1677–1683 | Cite as

Inhibition of TNF-α Improves Indomethacin-Induced Enteropathy in Rats by Modulating iNOS Expression

  • B. Saud
  • J. Nandi
  • G. Ong
  • S. Finocchiaro
  • R. A. Levine


TNF-α, including other proinflammatory cytokines alone or in combination, induces iNOS expression and upregulates inflammatory responses. We evaluated the relationship between TNF-α and iNOS expression in indomethacin-induced jejunoileitis in male Sprague–Dawley rats. Rats were fed a daily dose of a phosphodiesterase inhibitor—either theophylline or pentoxifylline—for 2 days. Jejunoileitis was induced with two subcutaneous injections of indomethacin (7.5 mg/kg) 24 hr apart and theophylline or pentoxifylline continued for 12 hr or 4 days. Other rats received a single intraperitoneal injection of anti-TNF-α monoclonal antibody (TNF-Ab) 30-min before indomethacin. At 4 days TNF-Ab, theophylline, or pentoxifylline treatment significantly decreased indomethacin-induced ulceration, myeloperoxidase activity, and disease activity index. Although indomethacin significantly increased serum TNF-α and nitrate/nitrite levels over the control value as early as 12 hr, iNOS expression was detected only after 4 days. Serum IL-1β level did not change at 12 hr but increased fourfold at 4 days. Treatment with TNF-Ab, theophylline, or pentoxifylline significantly reduced serum/tissue TNF-α, IL-1β, nitrate/nitrite, and iNOS expression. The downregulation of nitrate/nitrite by these inhibitors suggests that TNF-α modulates iNOS expression.


anti-TNF-α antibody phosphodiesterase inhibitor nitric oxide synthase intestinal ulceration 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Komatsu M, Koboyashi D, Saito K, Furuga D, Yagihashi A, Agaake H, Tsuji N, Sakamaki S, Niitsa Y, Watanabe N: Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem 47:1297–1231, 2001PubMedGoogle Scholar
  2. 2.
    Woywodt A, Lundwig D, Neostock P, Kruse A, Schwarting K, Jantschek G, Kirshner H, Stange EF: Mucosal cytokine expression, cellular markers and adhesion molecules in inflammatory bowel disease. Eur J Gastroenterol Hepatol 11:267–276, 1999PubMedGoogle Scholar
  3. 3.
    Sartor RB: Cytokines in intestinal inflammation: Pathophysiological and clinical considerations. Gastroenterology 106:533–539, 1994PubMedGoogle Scholar
  4. 4.
    Harendra de Silva DG, Mendis LN, Sheron N, Alexander GJM, Candy DCA, Chart H: Concentrations of interleukin G and tumor necrosis factor in serum and stools of children with Shigella dysenteriae 1 infection. Gut 36:194–198, 1993Google Scholar
  5. 5.
    Bertrand V, Guimband R, Tulliez M, Mauprivez C, Sogni P, Couturier D, Giroud JP, Chanssade S, Chauvelot ML: Increase in tumor necrosis factor-α production linked to toxicity of indo-methacin in the rat small intestine. Br J Pharmacol 124:1385–1394, 1998CrossRefPubMedGoogle Scholar
  6. 6.
    Santucci L, Fiorucci S, Giansanti M, Bounori PM, DiMatteo FM, Morelli A: Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: Role of tumor necrosis factor alpha. Gut 35:909–915, 1994PubMedGoogle Scholar
  7. 7.
    Grisham MB, Pavlick KP, Laroux FS, Hoffnan J, Bharwani S, Wolf RE: Nitric oxide and Chronic Gut Inflammation: Controversies in inflammatory bowel disease. J Invest Med 50:272–283, 2002Google Scholar
  8. 8.
    Baeverle PA, Baltimore D: NF-KB: Ten years after. Cell 87:13–20, 1996Google Scholar
  9. 9.
    Lopez-Belmonte J, Whittle BJR, Moncada S: The action of nitric oxide donors in the prevention on induction of injury to the rat gastric mucosa. Br J Pharmacol 108:73–78, 1993PubMedGoogle Scholar
  10. 10.
    Pique JM, Whittle BJR, Esplagues JV: The vasodilator role of endogenous nitric oxide in the gastric microcirculation. Eur J Pharmacol 174:293–296, 1989CrossRefPubMedGoogle Scholar
  11. 11.
    Parasher G, Frenklakh L, Goodman DR, Siddiqui T, Nandi J, Levine RA: Nitric oxide inhibitors ameliorate indomethacin induced enteropathy in rats. Dig Dis Sci 46:2536–2541, 2001CrossRefPubMedGoogle Scholar
  12. 12.
    Miller MJS, Thompson JH, Zhang XJ, Sadowska-Krowica H, Kakkis SL, Munshi UK, Sandoval M, Rossi JL, Eloby-Childress S, Beckman JS, Ye YZ, Rodi CP, Manning PT, Currie MG, Clark DA: Role of inducible nitric oxide synthase expression and peroxynitrite formation in guinea pig ileitis. Gastroenterology 109:1475–1483, 1995PubMedGoogle Scholar
  13. 13.
    Miller MJS, Sandoval M: Nitric oxide III. A molecular prelude to inflammation. Am J Physiol 226 (Gastrointest Liver Physiol 39):G795–G799, 1999Google Scholar
  14. 14.
    Grisham MB, Jourd Hevil D, Wink DA: Nitric oxide: I. Physiological chemistry of nitric oxide and its metabolites: implications in inflammation. Am J Physiol 276 (Gastrointest Liver Physiol 39):G315–G321, 1999Google Scholar
  15. 15.
    Spatafora M, Chiappara G, Merendino AM, D’Amico D, Bellia V, Bonsignore G: Theophylline suppresses the release of TNF- α by blood monocytes and alveolar macrophages. Eur Resp J 7:223–228, 1994Google Scholar
  16. 16.
    Reimund JM, Dumont S, Muller CD, Kenney JS, Kedinger M, Baumann R, Poindron P, Duclos B: In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease. Gut 40:475–480, 1997PubMedGoogle Scholar
  17. 17.
    Murthy SNS, Cooper HS, Shim H, Shah RS, Ibrahim SA, Sedergran DJ: Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporine. Dig Dis Sci 38:1722–1734, 1993CrossRefPubMedGoogle Scholar
  18. 18.
    Doherty GM, Christian J, Alexander HR, Buresh CM, Norton JA: Pentoxifyline suppression of tumor necrosis factor gene transcription. Surgery 110:192–198, 1991.PubMedGoogle Scholar
  19. 19.
    Nandi J, Meguid MM, Inui A, Xu Y, Makarenko IG, Tada T, Chung C: Central mechanisms involved with catabolism. Curr Opin Clin Nutr Metab Care 5:407–418, 2002CrossRefPubMedGoogle Scholar
  20. 20.
    Davies NM, Roseth AG, Appleyaod CB, McKnight W, Soldato P. del, Calignano A, Cioino G, Wallace JL: NO-naproxen vs naproxen: ulcerogenic, analgesic and anti inflammatory effects. Aliment Pharmacol Ther 11:69–79, 1997PubMedGoogle Scholar
  21. 21.
    Reuter BK, Wallace JL: Phosphodiesterase inhibitors prevent NSAID enteropathy independently of effects on TNF-α release. Am J Physiol 277 (Gastrointest Liver Physiol 40):G847–G854, 1999PubMedGoogle Scholar
  22. 22.
    Katz J, Willis J, Cooper G, Geraci K, Fiocchi C: Treatment of Crohn’s disease with pentoxifylline: Lack of correlation between clinical improvement and mucosal cytokine levels. Am J Gastroenterol 94:9(abstr 270), 1999Google Scholar
  23. 23.
    Samlaska CP, Winfeld EA: Pentoxifyline. J Am Acad Derm 30:603–621, 1994PubMedGoogle Scholar
  24. 24.
    Spies M, Chappeli VL, Dasu MR, Herndon DN, Thompson JC, Wolf SE: Role of TNF-α in gut mucosal changes after severe burn. Am J Physiol 283 (Gastrointest Liver Physiol 46):G703–G708, 2002Google Scholar
  25. 25.
    Podolsky DK: Inflammatory bowel disease. N Engl J Med 347:417–429, 2002CrossRefPubMedGoogle Scholar
  26. 26.
    Suenaert P, Bulteel V, Lemmens L, Noman M, Geypens B, Van Assche G, Geboes K, Ceuppens JL, Rutgeerts P: Anti-tumor necrosis factor treatment restores the gut barrier in Crohn’s disease. Am J Gastroenterol 97:2000–2004, 2002CrossRefPubMedGoogle Scholar
  27. 27.
    Totsuka T, Kanai T, Uraushihara K, Iiyama R, Yamazaki M, Akiba H, Yagita H, Okumura K, Watanabe M: Therapeutic effect of anti-OX40L and anti-TNF-α MAbs in a murine model of chronic colitis. Am J Physiol 284 (Gastrointest Liver Physiol 47):G595–G603, 2003Google Scholar
  28. 28.
    Nandi J, Saud B, Palma DT, Levine RA: 5-Aminosalicylic acid (5-ASA) improves indomethacin (INDO)-induced enteropathy by inhibiting iNOS transcription in rats. FASEB J 17:A659, 2003 (abstr)Google Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • B. Saud
    • 1
  • J. Nandi
    • 1
  • G. Ong
    • 1
  • S. Finocchiaro
    • 1
  • R. A. Levine
    • 1
  1. 1.Department of Medicine, Division of GastroenterologySUNY Upstate Medical UniversitySyracuseUSA

Personalised recommendations